Tozadenant (パーキンソン病)：医薬品市場予測及び分析（～2022）...市場調査レポートについてご紹介

1 Table of Contents
1 Table of Contents 5
1.1 List of Tables 8
1.2 List of Figures 9
2 Introduction 10
2.1 Catalyst 10
2.2 Related Reports 10
3 Disease Overview 13
3.1 Etiology and Pathophysiology 13
3.1.1 Etiology 13
3.1.2 Pathophysiology 16
3.1.3 Prognosis 18
3.1.4 Quality of Life 19
3.2 Symptoms 19
4 Disease Management 21
4.1 Overview 21
4.1.1 Diagnosis – The UK Brain Bank Criteria 21
4.1.2 Treatment Guidelines and Leading Prescribed Drugs 22
4.2 Treatment Synopsis 25
4.2.1 Dopaminergic Therapy Classes 25
4.2.2 Treatment of Parkinson’s Disease by Stage 27
4.2.3 Other Treatment Options 30
4.3 Parkinson’s Disease Assessment Scales 30
4.3.1 Unified Parkinson’s Disease Rating Scale (UPDRS) 31
4.3.2 Hoehn and Yahr Clinical Staging 33
4.3.3 Other Clinical Assessments 34
5 Competitive Assessment 35
5.1 Overview 35
5.2 Strategic Competitor Assessment 37
6 Opportunity and Unmet Need 38
6.1 Overview 38
6.2 Treatment of Motor Complications – Dyskinesias and OFF Episodes 40
6.2.1 Unmet Need 40
6.2.2 Gap Analysis 42
6.2.3 Opportunity 45
6.3 Treatment of Non-Motor Symptoms and Dementia 45
6.3.1 Unmet Need 45
6.3.2 Gap Analysis 46
6.3.3 Opportunity 48
6.4 Neuroprotective/Disease-Modifying Agents 48
6.4.1 Unmet Need 48
6.4.2 Gap Analysis 49
6.4.3 Opportunity 52
6.5 Improved Drug Formulations 53
6.5.1 Unmet Need 53
6.5.2 Gap Analysis 53
6.5.3 Opportunity 54
6.6 Identification of Reliable Biomarkers 54
6.6.1 Unmet Need 54
6.6.2 Gap Analysis 55
6.6.3 Opportunity 56
6.7 Improved Clinical Trial Design 56
6.7.1 Unmet Need 56
6.7.2 Gap Analysis 57
6.7.3 Opportunity 57
7 Pipeline Assessment 58
7.1 Overview 58
7.2 Promising Drugs in Clinical Development 58
8 Tozadenant 61
8.1 Overview 61
8.2 Efficacy 62
8.3 Safety 63
8.4 Dosing and Formulation 63
8.5 Potential Clinical Positioning 63
8.6 Potential Commercial Positioning 63
8.7 Pricing and Reimbursement 64
8.8 SWOT Analysis 64
8.9 Forecast 64
9 Appendix 66
9.1 Bibliography 66
9.2 Abbreviations 72
9.3 Methodology 76
9.4 Forecasting Methodology 76
9.4.1 Diagnosed Parkinson’s Disease Patients 76
9.4.2 Percent Drug-Treated Patients 77
9.4.3 General Pricing Assumptions 77
9.4.4 Compliance Assumptions 78
9.4.5 Individual Drug Assumptions 78
9.4.6 Generic Erosion 79
9.4.7 Pricing of Pipeline Agent 79
9.5 Physicians and Specialists Included in this Study 80
9.6 About the Authors 82
9.6.1 Author 82
9.6.2 Global Head of Healthcare 83
9.7 About GlobalData 84
9.8 Disclaimer 84